MetLife Investment Management LLC Has $67,000 Holdings in Perspective Therapeutics, Inc. $CATX

MetLife Investment Management LLC boosted its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 40.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,310 shares of the company’s stock after buying an additional 9,082 shares during the quarter. MetLife Investment Management LLC’s holdings in Perspective Therapeutics were worth $67,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. HighTower Advisors LLC increased its position in Perspective Therapeutics by 13.2% during the first quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock worth $429,000 after buying an additional 23,475 shares during the last quarter. Nuveen LLC acquired a new position in Perspective Therapeutics during the first quarter worth approximately $2,647,000. Charles Schwab Investment Management Inc. increased its position in Perspective Therapeutics by 6.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock worth $925,000 after buying an additional 27,119 shares during the last quarter. Citizens Financial Group Inc. RI increased its position in Perspective Therapeutics by 100.0% during the first quarter. Citizens Financial Group Inc. RI now owns 100,000 shares of the company’s stock worth $213,000 after buying an additional 50,000 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in Perspective Therapeutics during the first quarter worth approximately $288,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 4.2%

Shares of CATX stock opened at $3.23 on Thursday. The stock has a 50 day simple moving average of $3.74 and a 200 day simple moving average of $2.99. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.19.

Wall Street Analyst Weigh In

CATX has been the topic of a number of recent analyst reports. B. Riley reissued a “buy” rating and set a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Saturday, July 12th. Royal Bank Of Canada raised Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and upped their target price for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Finally, Truist Financial decreased their target price on Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $12.56.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.